TEVIMBRA Beigene Aus Pty Ltd
Product name
TEVIMBRA
Sponsor
Accepted date
Jul-2024
Active ingredients
tislelizumab
Proposed indication
For the treatment of recurrent or metastatic nasopharyngeal carcinoma.
Application type
C (new indication)
Publication date
Jul-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.